Obestatin
Overview
Obestatin is a 23-amino acid peptide hormone derived from post-translational processing of the ghrelin gene product preproghrelin. It was initially proposed to oppose ghrelin's orexigenic effects by binding to the GPR39 receptor and promoting satiety, though this mechanism remains controversial. The peptide has been investigated for potential roles in regulating food intake, gastrointestinal motility, and metabolic homeostasis.
Key Research Findings
Initial reports in 2005 suggested anorectic activity in rodents, but subsequent replication studies yielded inconsistent results and questioned the GPR39 binding hypothesis. Multiple independent laboratories have failed to confirm the original satiety effects, and the physiological role of obestatin remains unclear. Current evidence does not support a clinically meaningful role in appetite regulation.
Subcutaneous injection, Intravenous
Research Phase
Interested in Obestatin?
Find a verified provider experienced with Obestatin protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Obestatin ProviderRelated Peptides
CJC-1295
In Clinical TrialsA synthetic analog of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) that binds to albumin, extending its half-life from minutes to approximately 6-8 days. CJC-1295 stimulates pulsatile GH release from the anterior pituitary by binding to GHRH receptors while preserving the natural GH secretory pattern and negative feedback mechanisms.
Ipamorelin
In Clinical TrialsA highly selective growth hormone secretagogue that acts on ghrelin/GHS receptors in the pituitary gland to stimulate GH release. Unlike other GH secretagogues, ipamorelin does not significantly affect ACTH, cortisol, or prolactin levels, making it one of the most specific GH-releasing peptides. It works synergistically with GHRH analogs like CJC-1295.
Sermorelin
FDA ApprovedA synthetic 29-amino acid analog of GHRH representing the shortest fully functional fragment of the native 44-amino acid hormone. Sermorelin stimulates the pituitary to produce and release growth hormone through the natural GHRH receptor pathway, preserving the hypothalamic-pituitary feedback axis. It maintains physiological pulsatile GH secretion patterns.
Tesamorelin (Egrifta)
FDA ApprovedA synthetic GHRH analog consisting of the 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid modification at the N-terminus to improve stability. Tesamorelin specifically targets visceral adipose tissue reduction by stimulating lipolysis through GH-mediated pathways. It is the only FDA-approved treatment for HIV-associated lipodystrophy.